sacituzumab govitecan治疗晚期/转移性非小细胞肺癌的评估

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-05 DOI:10.1080/14737140.2025.2515989

Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas

{"title":"sacituzumab govitecan治疗晚期/转移性非小细胞肺癌的评估","authors":"Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas","doi":"10.1080/14737140.2025.2515989","DOIUrl":null,"url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).Areas covered: Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.Expert opinion: Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"845-852"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer.\",\"authors\":\"Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas\",\"doi\":\"10.1080/14737140.2025.2515989\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).Areas covered: Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.Expert opinion: Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"845-852\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2515989\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2515989","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

非小细胞肺癌（NSCLC）仍然是全球癌症相关死亡的主要原因。尽管靶向治疗和免疫检查点抑制剂取得了进展，但许多晚期非小细胞肺癌患者经历了疾病进展，需要新的治疗方法，如抗体-药物偶联（ADC）。研究领域：Sacituzumab govitecan是一种滋养细胞表面抗原2 （Trop-2）导向的ADC，已成为晚期NSCLC的潜在治疗方法。本综述评估了其作用机制、临床疗效、安全性和联合治疗的潜力，特别是在大量预处理的患者中。在PubMed上以关键词“sacituzumab govitecan”和“肺癌”进行文献检索，纳入相关研究，包括EVOKE-01试验。专家意见：Sacituzumab govitecan为对常规治疗无反应的患者提供了一个有希望的替代方案。虽然它显示出令人鼓舞的反应率和可控的毒性，但需要进一步的研究来完善患者选择和优化联合策略。正在进行的试验，如KEYNOTE-D46/EVOKE-3 2001年5月确定了其在一线非小细胞肺癌治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer.

Introduction: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).

Areas covered: Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.

Expert opinion: Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.